Aderonke Oluseye
Family · Glen Burnie, MDNPI 1881202406
Payments from drug & device makers
Across 101 payments — averaging $25.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$340
- Johnson & Johnson$176
- E.r. Squibb & Sons, L.L.C.$157
- Pharmaessentia USA Corporation$120
- Lilly USA, LLC$119
- Gilead$107
- plus $2K from 39 others
What the payments were for
- Food & beverage$2,585100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPDIVO$103
How this compares
$2,585 in reported general payments places this provider in the 85th percentile of 2,843 family providers in Maryland.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RevlimidLenalidomide | 30 | $537,843 |
| PomalystPomalidomide | 11 | $288,731 |
| Lenalidomide | 20 | $266,335 |
| SprycelDasatinib | 11 | $190,584 |
| VerzenioAbemaciclib | 12 | $185,426 |
| CalquenceAcalabrutinib Maleate | 11 | $166,879 |
| XareltoRivaroxaban | 53 | $69,003 |
| EliquisApixaban | 46 | $66,281 |
| Exemestane | 11 | $1,558 |
| Anastrozole | 61 | $1,514 |
| Letrozole | 42 | $1,295 |
| Hydroxyurea | 37 | $1,259 |
| Tamoxifen Citrate | 14 | $431 |
| Gabapentin | 18 | $308 |
| Ondansetron Hcl | 21 | $238 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Bristol Myers SquibbRevlimid | $29 | $537,84330 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst, Sprycel | $157 | $479,31522 claims |
| Lilly USA, LLCVerzenio | $119 | $185,42612 claims |
| AstraZenecaCalquence | $85 | $166,87911 claims |
| Johnson & JohnsonXarelto | $176 | $69,00353 claims |
| PfizerEliquis | $24 | $66,28146 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $14714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,843 family providers in Maryland.
Other family in Glen Burnie
- Mercy ViatorGlen Burnie$14K
- Melissa RiebenGlen Burnie$9K
- Ariana ChaoLutherville$727K
- Erika HoffmanPotomac$226K
- Caroline MansySalisbury$106K
- Hazel Jones-ParkerBaltimore$96K
- Brittany WilsonBaltimore$88K
- Meredith SagalHunt Valley$82K
- Sharon Dudley-BrownBel Air$67K
- Joy MaulikSalisbury$47K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.